Amitriptyline vs Duloxetine for Diabetic Peripheral Neuropathic Pain

June 2011
OB/GYN Clinical Alert;Jun2011 Clinical Brief, p12
The article discusses the double-blind crossover trial of amitriptyline and duloxetine in which these will be used as a treatment for diabetic peripheral neuropathic pain (DPNP).


Related Articles

  • Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, double-blind, noninferiority comparative study with pregabalin. Enomoto, Hiroyuki; Yasuda, Hitoshi; Nishiyori, Atsushi; Fujikoshi, Shinji; Furukawa, Masashi; Ishida, Mitsuhiro; Takahashi, Masashi; Tsuji, Toshinaga; Yoshikawa, Aki; Alev, Levent // Journal of Pain Research;Sep2018, Vol. 11, p1857 

    Purpose: Duloxetine and pregabalin are recommended as first-line treatments for diabetic peripheral neuropathic pain (DPNP). However, studies have not reported a direct comparison between duloxetine and pregabalin. We conducted a postmarketing, randomized, double-blind study to assess the...

  • Amitriptyline vs Duloxetine for Diabetic Peripheral Neuropathic Pain. Kuritzky, Louis // Infectious Disease Alert;Jun2011 Clinical Briefs in Primary, p12 

    The article discusses research by H. Kaur and colleagues which compared the efficiency of amitriptyline and duloxetine for diabetic peripheral neuropathic pain, published in a 2011 issue of "Diabetes Care."

  • Mechanisms and Management of Diabetic Painful Distal Symmetrical Polyneuropathy. Nickerson, D. Scott // Diabetes Care;May2014, Vol. 37 Issue 5, pe120 

    A letter to the editor is presented in response to the article "Mechanisms and Management of Diabetic Painful Distal Symmetrical Polyneuropathy" by S. Tesfaye and colleagues in the 2013 issue.

  • Amitriptyline vs Duloxetine for Diabetic Peripheral Neuropathic Pain. Kaur, H. // Internal Medicine Alert;5/29/2011 Supplement, p80 

    The article focuses on the double-blind crossover trial performed by H. Kaur and colleagues to compare the efficacy of amitriptyline with duloxetine in the treatment of diabetic peripheral neuropathic pain.

  • Cost-effectiveness Analysis of Pharmacologic Treatment of Fibromyalgia in Mexico. Arreola Ornelas, Héctor; Rosado Buzzo, Alfonso; García, Lourdes; Dorantes Aguilar, Javier; Contreras Hernández, Iris; Mould Quevedod, Joaquín F. // Reumatologia Clinica;may/jun2012, Vol. 8 Issue 3, p120 

    Objective: To identify, from the Mexican Public Health System perspective, which would be the most cost-effective treatment for patients with fibromyalgia (FM). Material and methods: A Markov model including three health states, divided by pain intensity (absence or presence of mild, moderate or...

  • Optimising Therapy for Patients with Neuropathic Pain. Westaway, Kerrie P.; Alderman, Christopher P.; Frank, Oliver R.; Husband, Alan J.; Rowett, Debra; Le Blanc, Tammy // Journal of Pharmacy Practice & Research;Mar2014, Vol. 44 Issue 1, p44 

    Neuropathic pain is a common condition that affects people of all ages, but is especially prevalent among older people because the incidence of many diseases that cause neuropathic pain increases with age. Neuropathic pain is often underdiagnosed or undertreated, and is associated with a...

  • Duloxetine.  // Reactions Weekly;4/23/2011, Issue 1348/1349, p16 

    The article describes the case of a 23-year-old man who acquired gynaecomastia and hypogonadism while undergoing treatment with duloxetine.

  • Duloxetine.  // Reactions Weekly;Aug2014, Vol. 1512 Issue 1, p20 

    The article presents two case studies of a 41-year-old woman and 47-year-old woman who were admitted to hospital for amenorrhoea and hyperprolactinaemia after being treated with duloxetine drug.

  • Duloxetine: Andrew Moore and colleagues reply to Des Spence. Moore, Andrew; Wiffen, Phil; Eccleston, Christopher; Lunn, Michael; Hughes, Richard; Williams, Amanda; Aldington, Dominic; Kalso, Eija // BMJ: British Medical Journal;2/22/2014, Vol. 348 Issue 7946, p20 

    The article highlights a reply to the article by Des Spence on how duloxetine loses power due to fact that most of what it is based on is wrong, which the authors also presented a non-comprehensive list of the points missed in the article.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics